SCNP Overview
Nodality has developed a breakthrough technology to analyze, at the single cell level, intracellular pathway proteins and their activation states after stimulation by biologically relevant modulators.
Nodality's proprietary technology, Single Cell Network Profiling (SCNP), is a proprietary system, based on intellectual property licensed from Stanford University. SCNP provides functional pathway analysis of signaling networks that regulate important cellular functions such as growth, proliferation, and survival.
The combination of a distinct protein in response to a specific modulator is called a node. This “node” activates when the cell signaling network responds to that specific modulator.
Why our technology is different
SCNP analyzes the functional activity of cells, at the single cell level, in hundreds of thousands or millions of cells. Utilizing tightly controlled systems, reagents, and custom-designed flow cytometry systems, SCNP measures the internal cell signaling networks before and after modulation with a biologically relevant modulator.
This approach reveals alterations in cellular networks that cannot be detected in resting cells or in larger populations of cells. Many of these alterations are known to play critical roles in the pathogenesis of cancer and autoimmune diseases. Using SCNP, Nodality is able to simultaneously evaluate multiple signaling nodes to identify the biologic diversity and therefore the therapeutic relevance in specific diseases.
Nodality applies SCNP for two distinct purposes:
- Drug development: drug profiling tools to compare drug candidates, reveal mechanism of action, determine PK/PD relationships, identify optimal drug combinations, and select patient responders
- Clinical medicine: the development of highly predictive clinical tests that better link individual disease biology to effective treatments - cialis 5mg pas cher en pharmacie
SCNP has been used to profile cells from bone marrow, peripheral blood, and circulating tumor cells to reveal insights in cancer and autoimmune diseases. A sample of biomarkers and pathways assessed is shown in the diagram below.